Latest for Cerebral Adrenoleukodystrophy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Cerebral Adrenoleukodystrophy
The disease progression in the cerebral form is rapid and relentless once inflammatory demyelination begins. Boys who were previously developing normally begin losing cognitive and motor function over months, progressing to a vegetative state and death, usually within 2-5 years of symptom onset without treatment. Hematopoietic stem cell transplant (HSCT) can halt progression if performed early, before significant neurological damage has occurred.
Keep reading about Cerebral Adrenoleukodystrophy
The gene therapy Skysona (elivaldogene autotemcel), from bluebird bio (renamed Genetix Biotherapeutics in 2025), received FDA accelerated approval in September 2022 for boys 4 to 17 with early, active cerebral ALD. Since August 2025 its label limits it to boys without an available HLA-matched stem cell donor and carries a strengthened boxed warning for blood cancer, which the label reports in 10 of 67 treated trial patients (15%).
In September 2026 the European Commission approved leriglitazone (Nezglyal), a daily medicine taken by mouth from Minoryx and its partner Neuraxpharm, for boys 2 to 12 with cerebral ALD whose brain lesions do not light up with gadolinium contrast on MRI. It is not approved in the U.S. Newborn screening that measures C26:0-lysophosphatidylcholine (C26:0-LPC), a marker of very-long-chain fatty acid buildup, in the heel-prick dried blood spot is now the standard for early detection, and serial MRI monitoring of at-risk boys enables treatment before irreversible damage occurs.
What are the symptoms of Cerebral Adrenoleukodystrophy?
These are common symptoms of Cerebral Adrenoleukodystrophy, and how strong they are varies from person to person.
- Learning difficulties and declining school performance
- Vision problems or progressive vision loss
- Behavioral changes, irritability, and social withdrawal
- Loss of coordination and balance
- Decline in previously learned skills like writing and speaking
- Progressive neurological decline including seizures and hearing loss
Who gets Cerebral Adrenoleukodystrophy?
Almost exclusively affects males due to X-linked inheritance. Cerebral form most commonly appears between ages 4 and 10. Females who carry one mutated ABCD1 gene may develop milder symptoms (adrenomyeloneuropathy) later in life. Newborn screening is now mandated in most U.S. states, enabling earlier detection.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Cerebral Adrenoleukodystrophy?
There is currently 1 FDA-approved medication for Cerebral Adrenoleukodystrophy.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Cerebral Adrenoleukodystrophy treatment
Charity funds and drugmaker programs for Cerebral Adrenoleukodystrophy, checked at the source.
- From a charity · United Leukodystrophy FoundationHultman Memorial Fund fundOpen
Pays for: Expenses directly related to the affected family member, based on demonstrated hardship (per 12 months), up to $500 per year.
The foundation says: “Applications are reviewed on a rolling basis as funding is available.”
Every program and fund for Cerebral Adrenoleukodystrophy, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Cerebral Adrenoleukodystrophy
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Cerebral Adrenoleukodystrophy resources
Reputable organizations and medical references for learning more about Cerebral Adrenoleukodystrophy, including disease registries, foundation resources, and clinical guidelines.